title: Treatment outcomes of adolescent acute lymphoblastic leukemia treated on Tokyo Children's Cancer Study Group (TCCSG) clinical trials.
abstract: There is no standard treatment for adolescents aged 15 years or older with acute lymphoblastic leukemia (ALL), although this age group has been reported as having a poorer prognosis compared to younger patients. We retrospectively analyzed the outcomes of three consecutive Tokyo Children's Cancer Study Group ALL trials (1995-2006) of 373 patients aged 10 years or older, with particular focus on adolescents aged 15-18 years (older-adolescents n = 41), compared to those aged 10-14 years (younger-adolescents n = 332). The probability of event-free survival at 8 years was 67.5 ± 7.4 % for the older-adolescents and 66.5 ± 2.6 % for the younger-adolescents (p = 0.95). Overall survival was 70.7 ± 7.1 % for the older-adolescents and 74.3 ± 2.4 % for the younger-adolescents (p = 0.48). The differences between groups in relapse incidence, non-relapse mortality, and death rate during induction were not statistically significant, although the older-adolescents trended towards a higher frequency of having stem-cell transplantation during the first remission. In conclusion, our treatment strategy, which consists of intensive induction and block-type consolidation, provided improved outcomes for patients aged 15-18 years, comparable to those for patients aged 10-14 years.
authors.affiliation: Department of Pediatrics, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan, katom-tky@umin.ac.jp.
authors.forename: Motohiro
authors.initials: M
authors.lastname: Kato
authors.forename: Atsushi
authors.initials: A
authors.lastname: Manabe
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Koh
authors.forename: Takeshi
authors.initials: T
authors.lastname: Inukai
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Kiyokawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Fukushima
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Goto
authors.forename: Daisuke
authors.initials: D
authors.lastname: Hasegawa
authors.forename: Chitose
authors.initials: C
authors.lastname: Ogawa
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Koike
authors.forename: Setsuo
authors.initials: S
authors.lastname: Ota
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Akira
authors.initials: A
authors.lastname: Kikuchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tsuchida
authors.forename: Akira
authors.initials: A
authors.lastname: Ohara
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome